The Association for the British Pharmaceutical Industry (ABPI) Code of Practice defines a Grant as funds, that are freely given for the purpose of supporting healthcare, scientific research, or education, with no consequent obligation on the recipient organisation to provide goods or services to the benefit of the pharmaceutical company in return. 

Grants must not:

• constitute an inducement to recommend and/or prescribe, purchase, supply, sell or administer specific medicines.
• be provided retrospectively.
• be provided to individuals.
• bear the name of any medicine.
• offset any normal operating expense.

Novo Nordisk will accept applications from:

• Hospitals and other healthcare organisations promoting patient care
• Universities engaged in life sciences innovation
• Patient Organisation/Advocacy groups

Examples of the types of application that will be considered include*:

• Projects/activities that support or improve care for those living with diabetes, obesity, and rare blood and rare endocrine diseases.
• Independent education for healthcare professionals.
• Independent education for patients, families, and caregivers to improve health outcomes and experience.
• Advancing the medical and scientific knowledge and understanding of diabetes, obesity, rare blood, and rare endocrine diseases.
• Advancing health policy research and education.

*This is not an exhaustive list

Novo Nordisk cannot consider applications that request funding for*:

• Stationary, furniture or IT equipment for healthcare organisations.
• Locum fees.
• Prizes or awards.
• Funding of social events and celebrations.

*This is not an exhaustive list

The following cannot be submitted via the Grant application process:

• Support in the form of a financial contribution for individuals to attend events/meetings.
• Clinical research, including Investigator Initiated Studies and Research Fellowships.
• Sponsorship of scientific meetings, events, or congresses.
• Collaborative Working or Joint Working projects.

Grant applications must be submitted via CyberGrants – see link below to access. Applications are reviewed by the Grant Panel on a quarterly basis. Please take care to include all relevant information at the time of the application, failure to do so will delay consideration of your application and/or result in it being rejected. Once the application has been received it can take up to 12 weeks for a decision to be made. The status of an application can be viewed within CyberGrants. 

Click here to apply for a grant

Where an application is successful, a contract will be put in place between Novo Nordisk and the recipient organisation. Following signing of the contract, the recipient organisation will be required to issue an invoice to Novo Nordisk for the Grant before payment can be made. Novo Nordisk will perform follow up with the recipient at the end of the Grant term to ensure the Grant has been used for the intended purpose and to check if any funding remains unspent. All Grants will be publicly disclosed in accordance with ABPI Code of Practice requirements. See Disclosure UK for further details: About Disclosure UK (abpi.org.uk)